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Abstract The kidney plays an important role in ion
homeostasis in the human body. Several hereditary disor-
ders characterized by perturbations in renal magnesium
reabsorption leading to hypomagnesemia have been de-
scribed over the past 50 years, with the most important of
these being Gitelman syndrome, familial hypomagnesemia
with hypercalciuria and nephrocalcinosis, familial hypo-
magnesemia with secondary hypocalcemia, autosomal
dominant hypomagnesemia with hypocalciuria, and auto-
somal recessive hypomagnesemia. Only recently, following
positional cloning strategies in affected families, have
mutations in renal ion channels and transporters been
identified in these diseases. In this short review, I give an
update on these hypomagnesemic disorders. Elucidation of
the genetic etiology and, for most of these disorders, also
the underlying pathophysiology of the disease, has greatly
increased our understanding of the normal physiology of
renal magnesium handling. This is yet another example of
the importance of studying rare disorders in order to
unravel physiological and pathophysiological processes in
the human body.
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Physiology and pathophysiology of magnesium handling
Magnesium (Mg2+) is the second-most abundant intracel-
lular cation and plays an essential role in a wide variety of
biological activities. Normal Mg2+ concentration (0.75–
1.4 mmol/L) in the human body is balanced by changes in
urinary Mg2+ excretion in response to altered uptake by the
intestine. The main site of absorption is the small bowel
where approximately one third of dietary Mg2+is absorbed.
Some additional absorption takes place in the large bowel.
Absorption in the small bowel occurs via paracellular
simple diffusion at high intraluminal concentrations and,
at low concentrations, by active transcellular uptake via the
recently identified Mg2+ channel TRPM6 (transient recep-
tor potential channel melastatin 6), which is expressed
along the brush border membrane of the small intestine [1].
Regulation and fine-tuning of serum the Mg2+ concentra-
tion occurs primarily in the kidney. Approximately
2500 mg of Mg2+ is filtered per day, of which 96% is
reabsorbed along the nephron and only a small portion (5–
15%) in the proximal tubule. The major site of passive
reabsorption is the thick ascending limb (TAL) of Henle’s
loop, where 50–72% of the filtered Mg2+ is reabsorbed
through the paracellular pathway. Active reabsorption of
Mg2+ takes place in the distal convoluted tubule (DCT) and
accounts for 10% of the total filtered load. Because the
DCT is the last site of Mg2+ reabsorption, the final urinary
secretion of Mg2+ is determined here. The epithelial Mg2+
channel, TRPM6, is essential for the apical influx of Mg2+
in DCT cells. The mechanisms of cytosolic Mg2+ diffusion
and basolateral transport of Mg2+ are not yet clear.
Hypomagnesemia is a common finding in hospitalized
patients and often an acquired disorder resulting from
deficient oral intake or accelerated urinary or intestinal loss.
Acquired renal magnesium wasting is commonly caused by
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drug therapy (i.e. diuretics, aminoglycosides, immuno-
suppressive agents), alcohol, and osmotic diuresis (i.e.
diabetes mellitus). Hypomagnesemia has also recently been
described as a frequent, and sometimes severe, side effect
of cetuximab therapy, a monoclonal antibody against the
epidermal growth factor receptor (EGFR) used in the
treatment of colorectal cancer [2].
The most important genetic causes of hypomagnesemia
are summarized in Table 1 and will be discussed in more
detail below
Hypomagnesemic disorders caused by defects localized
in the TAL
Familial hypomagnesemia with hypercalciuria and
nephrocalcinosis
Familial hypomagnesemia with hypercalciuria and neph-
rocalcinosis (FHHNC; OMIM 248250) is an autosomal
recessive renal disorder characterized by excessive renal
Mg2+ wasting, resulting in persistent hypomagnesemia,
renal Ca2+ wasting, bilateral nephrocalcinosis, and progres-
sive renal failure [3–6]. Symptoms usually begin in the first
few months of life. Affected individuals present with
recurrent urinary tract infections, polyuria/polydipsia, neph-
rolithiasis, and/or failure to thrive. Additional symptoms at
manifestation include abdominal pain, convulsions, muscu-
lar tetany, incomplete distal renal tubular acidosis, and
hypocitraturia [3, 4, 7, 8]. Some authors have reported
elevated serum parathyroid hormone levels early in the
course of the disease [3, 7]. Hyperuricemia is observed in
the majority of patients [3, 9, 10]. Ocular abnormalities
(severe myopia, nystagmus and chorioretinitis) and hearing
impairment have been reported as inconsistent extrarenal
symptoms in FHHNC [6].
Renal function declines progressively in approximately
30% of FHHNC patients, and many of these patients reach
end-stage renal disease in their teenage or young adult years
[11]. Most patients with FHHNC are initially treated with
oral citrate, thiazides, and high-dose enteral magnesium,
which may normalize some biochemical abnormalities but
do not always result in delayed progression of renal
dysfunction [3, 6, 11, 12].
Table 1 Inherited disorders of magnesium transport
Disease/OMIMa Gene/
inheritanceb
Proteinb Key clinical/biochemical symptoms





Familial hypo-magnesemia with hypercalciuria
and nephrocalcinosis/ 248250/248190
CLDN16/AR Claudin-16 Polyuria


















Autosomal recessive isolated renal Mg loss EGF/AR Epidermal growth factor Tetany/seizures
Hypomagnesemia
Normocalciuria
a Online Mendelian Inheritance in Man numbers. Available at: http://www.ncbi.nlm.gov/omim/OMIM
bAR, Autosomal recessive; AD, autosomal dominant; SLC, solute carrier; EGF, epidermal growth factor; TRPM6, transient receptor potential
channel melastatin 6, CLDN, claudin; NCC, NaCl cotransporter
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Thus, the overall prognosis of FHHNC is poor, and a
definite cure can only be achieved by renal transplantation.
In most cases, FHHNC is caused by loss-of-function
mutations in the CLDN16 gene, which encodes claudin-16
(formerly paracellin-1), an important tight junction protein
of the claudin family, that is expressed in the TAL of
Henle’s loop and in the DCT [11–14]. The claudin family
comprises a set of structurally related proteins involved in
the formation of tight junction proteins in various tissues
[15]. The mutations in CLDN16 identified in FHHNC
patients consist of premature termination codons, splice-site
mutations, and missense mutations, all of which are located
within the extracellular loops or the transmembrane
domains of the claudin-16 protein [11–14]. In Germany
and Eastern European countries a founder mutation
(L151F) in the first extracellular loop of claudin-16 has
been identified that is present in approximately 50% of
mutant alleles [11]. This finding greatly facilitates molec-
ular diagnosis in patients originating from these countries.
Konrad et al. recently reported that patients who have
FHHNC and are affected by two loss-of-function mutations
in the CLDN16 gene have an early onset of chronic renal
failure, whereas patients with at least one mutation with
residual function are protected from the rapid loss of renal
function [14].
Interestingly, a novel homozygous CLDN16 mutation
(T233R) has been identified in two families with self-
limiting childhood hypercalciuria. The hypercalciuria de-
creased with age and was not associated with declined renal
function. The T233R mutation is the first mutation to be
identified in the cytosolic tail of claudin-16 and results in
inactivation of the PDZ-domain-binding motif. This inac-
tivation abolishes the association with the tight-junction
scaffolding protein ZO-1, with subsequent accumulation of
the mutant claudin-16 protein in lysosomes and no
localization to the tight junction [16]. These findings
indicate that the clinical phenotype of mutations in
claudin-16 is likely to be determined by the location of
the mutation within the gene; mutations affecting amino
acids at the extracellular and transmembrane segments
cause classical FHHNC, while mutations affecting specific
amino acids in the cytosolic domain cause a spontaneously
resolving hypercalciuria.
In a subset of families with FHHNC and severe ocular
involvement (OMIM 248190), the disease was shown to be
caused by mutations in the CLDN19 gene, which encodes
claudin-19, another important tight junction protein
expressed in renal tubules and the eye [17].
The precise function of claudin-16 and -19 and their role
in FHHNC remain to be elucidated. It was initially assumed
that claudin-16 has high selective paracellular permeability
for magnesium and calcium. However, based on the results
of electrophysiological studies in LLC-PK1 epithelial cells
expressing human claudin-16, Hou and coworkers reported
that claudin-16 has only a low permeability for magnesium,
but a much higher one for sodium. These researchers
proposed that claudin-16 may form a paracellular shunt for
sodium from the interstitium to lumen, thereby contributing
to the lumen positive potential [18]. This proposal was
further substantiated in a mouse model with highly reduced
claudin-16 expression, which displayed magnesuria and
calciuria, loss of bone mass, and nephrocalcinosis. Detailed
analysis of the TAL function in this model revealed
decreased paracellular sodium permeability and strongly
reduced lumen positive potential [19]. Taken together, these
findings strongly suggest that claudin-16 is part of the tight
junction complex that selectively mediates sodium backleak
into the TAL lumen, thereby generating a higher lumen
positive potential, which is critical for paracellular reab-
sorption of sodium and magnesium (Fig. 1).
Hypomagnesemic disorders caused by defects localized
in the DCT
Gitelman syndrome
Gitelman syndrome (GS) (OMIM 263800) is an autosomal
























Fig. 1 Speculative model of magnesium transport in the thick
ascending limb of Henle’s loop. Sodium chloride enters the cell via
the apical Na+, K+, 2Cl – cotransporter (NKCC2). Potassium is
recycled into the lumen via the luminal ATP-regulated inwardly
rectifying potassium channel (ROMK2). Chloride leaves the cell
through the basolateral Cl- channel (ClC-Kb) and sodium via the
basolateral Na+/K+-ATPase complex. A lumen-positive potential (PD)
is established by the actions of NKCC2 and ROMK2. Sodium
partially leaks back into the lumen via claudin-16, increasing this
lumen positive potential, thereby driving magnesium and calcium
reabsorption via the paracellular pathway
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by hypomagnesemia, hypocalciuria, and secondary aldo-
steronism which is responsible for hypokalemia and
metabolic alkalosis [20]. The prevalence is estimated at
approximately 25 per million and, accordingly, the preva-
lence of heterozygotes is approximately 1% in Caucasian
populations, making it one of the most frequent inherited
renal tubular disorders [21].
Patients with GS usually present above the age of 6
years, and in many cases the diagnosis is only made at adult
age. Most patients suffer from tetany, especially during
periods of fever or when extra magnesium is lost due to
vomiting or diarrhea. Paraesthesias, especially in the face,
frequently occur. Some patients experience fatigue so
severe that it interferes with daily activities, while others
never complain of tiredness. The severity of fatigue in GS
is not completely related to the degree of hypokalemia. In
contrast to Bartter syndrome, which is a genetically distinct
and clinically more severe tubular transport disorder that
shares the hypokalemic metabolic alkalosis with GS,
polyuria is usually absent or only mild in GS. In general,
growth is normal in GS patients; however, it can be delayed
in patients with severe hypokalemia and severe hypomag-
nesemia [22]. Many adult GS patients suffer from chon-
drocalcinosis, which is assumed to result from chronic
hypomagnesemia [23]. This condition causes swelling,
local heat, and tenderness over the affected joints. Cruz
and colleagues have challenged the generally accepted idea
that GS is a mild disorder [24]. They evaluated the
symptoms and quality of life (QOL) in 50 adult patients
with molecularly proven GS and compared this cohort of
patients with 25 age- and sex-matched controls. They found
that GS patients had significantly more complaints than
controls, mainly salt craving, musculoskeletal symptoms,
such as cramps, muscle weakness, and aches, and consti-
tutional symptoms, such as fatigue, generalized weakness
and dizziness, and nocturia and polydipsia. In addition,
measures of QOL were significantly lower in GS patients
than in controls.
Potassium and magnesium depletion prolong the dura-
tion of the action potential of cardiomyocytes and conse-
quently increase the risk of developing ventricular
arrhythmia. Electrocardiograms of patients with GS have
shown that in about 50% of cases the QT interval is indeed
slightly to moderately prolonged but, fortunately, is not
associated with clinically relevant cardiac arrhythmias in
the far majority of cases [25]. Sudden cardiac arrest has
been reported in a few patients with GS [22, 26], indicating
the advisability of systematic cardiac screening for such
patients in order to identify other possible triggering
mechanisms or underlying conditions. Blood pressure in
GS patients is lower than in the general population,
indicating that even the modest salt wasting of this disease
reduces blood pressure. The results from a recent study in
35 GS carriers (with one mutant gene allele) suggest that
GS carriers also have lower blood pressure and may be
protected from hypertension [27]. Another study in a large
cohort also demonstrated reduced blood pressure in
subjects having one mutant gene allele [28]. These results
are distinct from those reported in a previous study in an
Amish kindred, in which no reduction of blood pressure
was demonstrated in adult patients, despite increased Na+
excretion [29]. Thus, further studies are required to
investigate whether the incidence of cardio-vascular events
differs between GS patients or carriers compared to the
control population.
The diagnosis of GS is based on clinical symptoms and
biochemical abnormalities. The most typical biochemical
abnormalities in GS patients are hypokalemia, hypomagne-
semia, and hypocalciuria. Compared to Bartter syndrome,
serum potassium concentration is comparably low (2.7±
0.4 mmol/L). Serum magnesium concentration is low (less
than 0.65 mmol/L). In a small number of GS patients it is
possible to easily maintain the magnesium concentration in
the normal range early on, which may lead to a false
diagnosis of Bartter syndrome; in these patients, the
magnesium concentration only drops below normal with
time (personal observation). Hypomagnesemia and hypo-
calciuria have always been considered obligate features for
GS. This assumption has been disputed by Lin et al. [30]
who reported two families with molecularly proven GS in
which male patients had severe hypokalemia and were
symptomatic with episodes of paralysis, impaired urinary
concentration ability, but with normal serum magnesium
and urinary calcium excretion. Remarkably, female GS
patients within these families, carrying the same causative
mutations as the male patients, were asymptomatic, had less
severe hypokalemia, and maintained intact urine concen-
tration ability, but they did have hypomagnesemia and
hypocalciuria [30]. Although this was a small study, the
authors concluded that gender may affect phenotypic
expression in GS and that hypomagnesemia and hypocal-
ciuria may not be invariant features of the disorder.
Prostaglandin excretion is normal, and plasma renin
activity and plasma aldosterone concentration are only
slightly elevated compared to Bartter syndrome. Renal
functional studies have demonstrated a normal or slightly
decreased urinary concentrating mechanism, but clearly
reduced distal fractional chloride reabsorption during
hypotonic saline infusion. Patients with GS have a blunted
natriuretic response to hydrochlorothiazide administration,
but a prompt natriuresis after administration of furosemide,
indicating that the defect in GS is located at the level of the
distal tubule.
Most patients with GS remain untreated. However, in
view of the assumption that chondrocalcinosis is due to
magnesium deficiency, there is a clear argument for lifelong
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supplementation of magnesium. Normalization of serum
magnesium is difficult to achieve since high doses of
magnesium cause diarrhea. The bioavailability of magne-
sium preparations is different. Magnesium oxide and
magnesium sulfate have a significantly lower bioavailabil-
ity than magnesium chloride, magnesium lactate, and
magnesium aspartate [31]. Hypokalemia can be treated by
drugs that antagonize the activity of aldosterone or block
the epithelial sodium channel (ENaC) in the collecting duct.
We prefer the combination of amiloride with KCl.
In general, the long-term prognosis of GS is good.
However, the severity of fatigue may seriously hamper
some patients in their daily activities. Progression to renal
insufficiency is extremely rare in GS. As yet, only one
patient who developed chronic renal insufficiency and
subsequent progression to end-stage renal disease has been
reported [32].
In the great majority of cases, GS is caused by mutations in
the solute carrier family 12, member 3, SLC12A3 gene, which
encodes the renal thiazide-sensitive sodium chloride co-
transporter (NCC) that is specifically expressed in the apical
membrane of cells in the first part of the DCT (reviewed in
[33]). The NCC is a 1021-amino acid polypeptide, and the
two-dimensional structure is predicted to contain 12 trans-
membrane domains and long intracellular amino- and carboxy-
termini [34]. At present, more than 140 different putative
loss-of-function mutations in the SLC12A3 gene have been
identified in GS patients (collected in Human Gene Mutation
Database HGMD, http://www.hgmd.cf.ac.uk/). Most are mis-
sense mutations substituting conserved amino acid residues
within putative functional domains of NCC, whereas non-
sense, frameshift-, and splice-site mutations and gene rear-
rangements are less frequent.
Functional expression studies and immunocytochemistry
analyses of Xenopus leavis oocytes revealed that most
disease-causing NCC mutants belong to the so-called type
2 mutations. These type 2 mutations are missense mutations
or insertions/deletions of one or more nucleotide triplets,
resulting in fully translated proteins. Due to the mutation,
however, these mutant receptors are misfolded and retained
in the endoplasmic reticulum (ER), as the ER is the organelle
that has the cellular quality control over proper folding and
maturation of synthesized proteins. Misfolded proteins are
subsequently targeted for proteasomal degradation. De Jong
and coworkers have shown that NCC misfolding resulting in
defective trafficking to the plasma membrane in GS is not
uniformly complete [35]. Some mutant NCC proteins are
only partially retarded in their trafficking; they do reach the
plasma membrane, albeit to a limited extent, and are partially
active. It was subsequently demonstrated that the intrinsic
activity of these partially retarded mutants is unaffected by
the mutation [36, 37]. This finding opens the possibility of
using pharmacological chaperones that facilitate the routing
of trafficking-defective—but otherwise functional—NCC
proteins to the apical membrane for therapeutic use.
Another class of mutations in GS has been recently iden-
tified by Riveira-Munoz et al. [38]. This newly identified
class includes mutants that are partly retained in the cell. In
contrast to the mutants mentioned above, however, these
mutants do not show any functional activity and, conse-
quently, pharmacological chaperones will not be of any
therapeutic use.
In general, there is extreme inter- and intrafamiliar
phenotype variability in GS, the latter emphasizing the lack
of a correlation between the severity of symptoms in GS
and the type of mutation in the SLC12A3 gene [30].
Recently, however, Riviera-Munoz et al. described a small
subgroup of patients with a remarkable severe phenotype,
including an early onset, severe neuromuscular manifes-
tations, growth retardation, and ventricular arrhythmias
[22]. The majority of these patients was male and carried
at least one splice-site mutation, resulting in a truncating
transcript, or a non-functional intracellularly retained
mutation. Based on their data, these researchers suggested
that the nature/position of the SLC12A3 mutation combined
with male gender may be a determinant factor in the
severity of GS. Studies in lager cohorts are necessary to
confirm this proposal.
A minority of patients with the Gitelman phenotype has
been shown to have mutations in the CLCNKB gene, which
encodes the renal chloride channel ClC-Kb, located in
basolateral membrane of cells of the TAL of Henle’s loop
and the distal tubules. Mutations in the CLCNKB gene were
originally found to be the cause of classic Bartter syndrome
[39, 40]. It is now evident that the clinical phenotype in
patients with CLCNKB mutations can be highly variable,
varying from an antenatal onset of Bartter syndrome on one
side of the spectrum to a phenotype closely resembling GS
on the other side (review in [33]). Therefore, there is a
medical indication to screen the CLCNKB gene in patients
with the Gitelman phenotype who do not have mutations in
the SLC12A3 gene.
Both loss-of-function mutations in NCC and mutations
in CLC-Kb lead to disruption of NaCl reabsorption in the
DCT (Fig. 2). When less NaCl is reabsorbed, more sodium
will arrive in the collecting duct, resulting in mild volume
contraction. The reduced vascular volume activates the
renin–angiotensin system, increasing renin activity and
aldosterone levels. The elevated aldosterone levels give
rise to increased electrogenic sodium reabsorption in the
cortical collecting duct via the ENaC, defending salt
homeostasis at the expense of increased secretion of
potassium and hydrogen ions, thus resulting in hypokale-
mia and metabolic alkalosis.
Passive Ca2+ reabsorption in the proximal tubule and
reduced abundance of the epithelial Mg 2+ channel TRPM6,
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which is located in the DCT, has been shown to explain
thiazide-induced hypocalciuria and hypomagnesemia,
respectively [41]. Since thiazides are known to inhibit
NCC, and in view of the phenotypic resemblance between
GS and chronic thiazide-treatment, it is very likely that
similar mechanisms are involved in the pathogenesis of
the hypocalciuria and hypomagnesemia, respectively, seen
in GS patients.
Autosomal dominant renal hypomagnesemia with
hypocalciuria
Autosomal dominant renal magnesium wasting (HOMG2;
OMIM 154020), is characterized by hypomagnesemia due
to renal magnesium loss and is associated with hypocalciu-
ria [42]. Patients may suffer from generalized convulsions,
but they may also be asymptomatic, except for the
development of chondrocalcinosis at an adult age. The
genetic defect identified in a large Dutch family with this
disorder appeared to be a heterozygous missense mutation
(G41R) in the FXYD2 gene, which encodes the γ-subunit
of the basolateral Na+/K+-ATPase which, in turn, is
expressed in the basolateral membrane of epithelial cells
of the DCT [43]. This γ-subunit has an important role in
modulating the activity of the Na+/K+-ATPase, which
maintains the membrane potential and the Na+ gradient
[44]. Expression studies in different cell lines have revealed
that the mutation in the γ-subunit abolishes its interaction
with the αβ subunits of the Na+/K+-ATPase, resulting in a
failure of γ to traffic to the cell surface and to modulate
pump kinetics [43, 45]. The measurement of serum Mg2+
concentration in two individuals with a heterozygous
11q23-ter deletion (including the FXYD2 gene) revealed
that both individuals had normal serum Mg2+ values,
indicating that the loss of one FXYD2 gene copy is not
sufficient to cause a Mg2+-deficient phenotype [43]. These
findings strongly suggest that the hypomagnesemia in the
patients with FXYD2 mutations is caused by a dominant
negative effect rather than by haploinsufficiency. The recent
finding that Fxyd2 knockout mice have normal serum Mg2+
levels and do not show any abnormalities in Mg2+ excretion
is consistent with this assumption [46].
The exact molecular mechanism of hypomagnesemia and
the associated hypocalciuria in patients with FXYD2 muta-
tions remains to be elucidated. It has been speculated that
abrogation of γ-mediated modulation of the Na-K-ATPase
kinetics changes the electrochemical gradients of Na+ and
K+, with a secondary reduction in Mg2+ reabsorption through
the apical TRPM6 channel [47].
Kantorovich et al. recently described another family with
autosomal dominant isolated hypomagnesemia, in which
they excluded linkage to the chromosomal region of 11q23
containing the FXYD2 gene [48]. Thus, there is clear
evidence for locus heterogeneity for this phenotype.
Familial hypomagnesemia with secondary hypocalcemia
Familial hypomagnesemia with secondary hypocalcemia
(HSH) is a rare autosomal recessive disorder that manifests
in the newborn period and is characterized by very low
serum Mg2+ (0.2 mmol/L) [49]. Hypocalcemia is another
characteristic feature of this disorder and is a secondary
consequence of parathyroid failure and parathyroid hor-
mone (PTH) resistance as a result of chronic, severe
hypomagnesemia [50]. The disease typically manifests
during the first months of life with generalized convulsions
or signs of increased neuromuscular excitability, such as
muscle spasms or tetany [51]. Untreated, the disease may
be fatal or may lead to severe neurological damage [51, 52].
The immediate administration of magnesium, usually via
the intravenous route, followed by lifelong-treatment with
high-dose oral magnesium assures the relief of clinical
symptoms and normalization of calcium metabolism [52].
In contrast, serum magnesium levels usually fail to reach
normal values under oral substitution therapies and remain























Fig. 2 Speculative cellular model of magnesium transport in the distal
convoluted tubule. Magnesium is reabsorbed by the apical transient
receptor potential channel melastatin 6 (TRPM6) channel. Indicated also
is a putative Na/Mg exchanger in the basolateral membrane, which may
be responsible for extrusion of Mg2+. The Na+/K+-ATPase complex,
including the γ-subunit, controls this transcellular Mg2+ transport. Pro-
epithelial growth factor (Pro-EGF) expressed on the basolateral mem-
brane is cleaved to yield EGF, engaging the EGF receptor (EGFR) which
in turn stimulates TRPM6 activity. Also indicated are the apical thiazide-
sensitive NaCl cotransporter (NCC), through which sodium chloride
enters the cell, and the basolateral Cl- channel (ClC-Kb) and Na+/K+-
ATPase that are responsible for extrusion of these ions. Both the NCC
and CLC-Kb are involved in GS
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Familial HSH is caused by mutations in the TRPM6
gene, which encodes the TRPM6 protein [51, 53, 54]. This
protein belongs to the melastatin-related group of a large
family of transient receptor potential (TRP) cation channels
that play an important role in a wide variety of physiolog-
ical processes, ranging from thermal, tactile, taste, osmolar,
and fluid flow sensing to transepithelial Ca2+ and Mg2+
transport [55]. Detailed electrophysiological analyses and
expression studies have demonstrated that TRPM6 confines
a Mg2+-permeable channel, which is specifically localized
to the apical membrane of Mg2+- reabsorbing tubules in the
kidney (DCT) and the brush-border membrane of the Mg2+-
absorptive cells in the small intestine [1] (Fig. 2). By far the
majority of mutations found in HSH patients introduce stop
codons, deletions of exons, and frameshifts or affect splice
sites, thus resulting in a complete loss-of-function of
TRPM6 protein [51]. These inactivation mutations cause
the combination of impaired gut reabsorption of Mg2+ and
renal wasting seen in HSH.
Isolated autosomal recessive hypomagnesemia (IRH)
The disease gene in a very rare form of primary hypomag-
nesemia, called isolated autosomal recessive renal hypo-
magnesemia (IRH; OMIM 611718), has very recently been
identified. This disease was identified 20 years ago in two
Dutch sisters from consanguineous parents, who showed
psychomotor retardation and epileptic seizures during child-
hood and who as adults were moderately mentally retarded
[56]. Both affected sisters had very low serum Mg2+ levels,
while their urinary Mg2+ excretion was in the normal range,
pointing to a disturbance in the tubular reabsorption of Mg2+.
Apart from hypomagnesemia, no other abnormalities were
identified and, in particular, there was no disturbance in
urinary calcium excretion. Using a whole genome homozy-
gosity-based mapping strategy followed by fine-mapping,
Groenestege et al. identified a critical linkage region of
25.7 cM on chromosome 4. Within this region, the EGF gene
encoding the pro-epidermal growth factor (pro-EGF) was
proven to be the disease gene, based on the identification of
a homozygous mutation, C3209T in exon 22 in both affected
sisters. This mutation caused the substitution of the highly
conserved proline 1070 within the cytoplasmic tail of pro-
EGF by leucine (P1070L). Both of parents of the patient, as
well as the unaffected sisters were heterozygous for the
mutation [57].
Pro-epidermal growth factor is a type-one membrane
protein that is expressed at high level in the luminal and at a
low level at the basolateral membranes of the DCT [58–60].
It is cleaved by extracellular proteases to generate the active
EGF in luminal and basolateral spaces. In a kidney cell line,
Groenstege et al. demonstrated that EGF binding to its
receptor (EGFR) is essential for the function of TRPM6,
which controls magnesium reabsorption in the kidney [57].
As a result of the IRH-associated P1070L mutation, pro-
EGF targeting to the basolateral membrane is disrupted,
thereby leading to reduced EGF production in the baso-
lateral space and, consequently, inadequate stimulation of
the EGFR on the basolateral membrane. As a result,
TRPM6 is insufficiently activated, causing magnesium
loss. This model is compatible with the hypomagnesemia
previously observed in colon cancer patients treated with
the anti-EGF receptor antibody cetuximab [2]. In support of
this mechanism, it has been shown that cetuximab also
antagonizes the stimulation of TRPM6 activity by EGF in
cultured cells [57].
Conclusion
The etiology and pathophysiology of a significant number
of inherited disorders associated with disturbances of renal
magnesium transport has been elucidated in recent years.
With the knowledge that has been gained, our insight into
the physiology of renal magnesium handling has increased
significantly. Nevertheless, the molecular mechanisms
responsible for the basolateral extrusion of magnesium in
the distal convoluted tubule are still completely unknown.
Future identification of gene defects in other forms of renal
magnesium loss, proven not to be caused by the known
disease genes, will be of great help in finding these pieces
in the magnesium-transport puzzle.
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